Akademik Veri Yönetim Sistemi
FENS 2024, Athens, Yunanistan, 23 - 26 Haziran 2024, ss.24
. In our study, we aimed to investigate the effects of different doses of the new antiepileptic drug Lacosamide on schizophrenia models and compare it with typical and atypical antipsychotic drugs. Wistar male rats (250-300 g) and cd-1 male mice (25-35 g) were used. The rats were divided into 9 groups and received drug treatment for 5 days. On Day 5, MK-801 injection was made 1 hour after the last dose of drug treatment. The rats were subjected to Prepulse Inhibition Inhibition (P.P.I) and Passive Avoidance tests, respectively. Cd1 albino mice were also given drug treatment for 5 days and climbing, catalepsy and locomotor activity tests were performed. Statistical analyzes were evaluated with one-way analysis of variance. MK-801 reduced mean %P.P.I. compared to control. The effect of MK-801 on P.P.I. was significantly reversed by MK-801+Lacosamide 30 mg/kg. The average % P.P.I. value in the MK-801+Lacosamide 30 mg/kg+Bikukulin group decreased significantly compared to the MK-801+Lacosamide 30 mg/kg group. While Lacosamide did not produce cataleptic behavior in mice, it reversed the effect of apomorphine-induced increase in climbing time. Although there is not a statistical difference in GABA levels in ELISA results, Lacosamide demonstrated GABA agonistic effect potential in behavioral tests. Considering that it does not show the effects seen in typical antipsychotic drugs in terms of its side effect profile, we think that more studies can be conducted on it as an adjunctive treatment alternative to classical antipsychotic treatment. Key Words: Lacosamide, Schizophrenia, P.P.I. , CRMP-2 Supported by by Eskişehir Osmangazi University Scientific Research Projects Coordination Office.